Title : Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review.

Pub. Date : 2014 Mar

PMID : 24106875






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Insulin and incretin agents (dipeptidyl peptidase-4 inhibitors [DPP4is] and glucagon-like peptide-1 receptor agonists [GLP1 RAs]) are second-line treatment options in patients with type 2 diabetes (T2D) not achieving glycemic targets with metformin. Metformin glucagon like peptide 1 receptor Homo sapiens